Clinical trial
A Phase 3 Open-label, Controlled, Randomised, Multi-centre Trial Comparing Imlifidase and Standard-of-care With Standard-of-care Alone in the Treatment of Severe Anti-GBM Antibody Disease (Goodpasture Disease)
NCT05679401 is registered in ClinicalTrials.gov with Hansa Biopharma AB as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Open-label, Controlled, Randomised, Multi-centre Trial Comparing Imlifidase and Standard-of-care With Standard-of-care Alone in the Treatment of Severe Anti-GBM Antibody Disease (Goodpasture Disease)
- Lead sponsor
- Hansa Biopharma AB
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- December 22, 2022
- Completion date
- February 2, 2026
- Enrollment
- 50 (actual)
- Sites
- 48
Conditions
As the registry lists them; a condition with its own page is linked.
anti-glomerular basement membrane antibody disease, anti-glomerular basement membrane disease, good pasture syndrome, goodpasture syndrome